Biotech Angel Investing

Biotech angel investing means backing life sciences companies — therapeutics, medical devices, diagnostics, digital health, and the tools and infrastructure that enable them — at the earliest stage, usually before institutional venture capital is involved. It sits in the same category as software angel investing in structure (individual checks, equity or SAFEs, board observer rights at most), but the underlying risk profile is genuinely different.

Software startups fail or succeed largely on execution and market timing; the technology usually works as described. Life sciences startups carry scientific and regulatory risk on top of execution risk — the biology, the device, or the algorithm has to actually do what the company claims, and a regulatory body or a clinical result often has the final word on timelines that software companies never face. That changes what due diligence needs to cover, how long capital needs to be patient, and why a scientific or clinical background is a real advantage rather than a nice-to-have.

It also changes the shape of returns. Biotech outcomes tend to be more binary than software outcomes — a drug candidate either clears its next trial or it does not — which is part of why many biotech angels build a portfolio of several smaller positions rather than concentrating in one or two companies, and why understanding the specific risks retired at each stage matters more than a general sense that “the science looks promising.”

What biotech angels are actually evaluating

Beyond the team and the market, the questions that matter most are usually: is the underlying evidence credible, is the development path to the next milestone realistic on the capital being raised, and are the manufacturing, regulatory, and clinical risks being retired in the right order. ChaosBio's investment thesis lays out the framework in full.